Current status of metals as therapeutic targets in Alzheimer's disease

Journal of the American Geriatrics Society

Volumn 51, Issue 8, 2003, Pages 1143-1148

  Finefrock, Anne E ^a   Bush, Ashley I ^b   Doraiswamy, P Murali ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

amyloid; Alzheimer's disease; Clioquinol; Copper; Zinc

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID VACCINE; CHELATING AGENT; CLIOQUINOL; COPPER; CYANOCOBALAMIN; DEFEROXAMINE; ENZYME INHIBITOR; IRON; METAL; SECRETASE INHIBITOR; UNCLASSIFIED DRUG; ZINC;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANEMIA; CHELATION THERAPY; CLINICAL TRIAL; COPPER METABOLISM; HUMAN; INJECTION PAIN; IRON METABOLISM; NEUROPIL; NEUROTOXICITY; PATHOPHYSIOLOGY; REVIEW; VITAMIN SUPPLEMENTATION; ZINC METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CHELATING AGENTS; CLIOQUINOL; COPPER; DEFEROXAMINE; DIET; HUMANS; IRON; ZINC;

EID: 0042021925     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2003.51368.x     Document Type: Review

References (43)

1. Maury CPJ. Molecular pathogenesis of beta-amyloidosis in Alzheimer's disease and other cerebral amyloidoses. Lab Invest 1995;72:4-16.
2. Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736.
3. Dovey HF, John V, Anderson JP et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001;76:173-181.
4. Schenk D, Games D, Seubert P. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and AB immunization. J Mol Neuro Sci 2001;17:259-267.
5. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-α attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
6. Lynch T, Cherny RA, Bush AI. Oxidative process in Alzheimer's disease. The role of Aβ-metal interactions. Exp Gerontol 2000;35:445-451.
7. Vigo-Pelfrey C, Lee D, Keim P et al. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 1993;61:1965-1968.
8. Masters CL, Multhaup G, Simms G et al. Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 1985;4:2757-2763.
9. Atwood CS, Moir RD, Huang X et al. Dramatic aggregation of Alzheimer Aβ by Cu (II) is induced by conditions representing physiological acidosis. J Biol Chem 1998;273:12817-12826.
10. Cuajungco MP, Faget KY, Huang X et al. Metal chelation as a potential therapy for Alzheimer's disease. Ann N Y Acad Sci 2000;920:292-304.
11. Lemere CA, Blusztajn JK, Yamaguchi H et al. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down's syndrome: Implications for initial events in amyloid plaque formation. Neurobiol Dis 1997;3:16-32.
12. Lovell MA, Robertson JD, Teesdale WJ et al. Copper, iron, and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52.
13. Suh SW, Jensen KB, Jensen MS et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000;852:274-278.
14. Lee JY, Mook-Jung I, Koh JY. Histochemically reactive zinc in plaques of the Swedish mutant B-amyloid precursor protein transgenic mice. J Neurosci 1999;19:RC10.
15. Huang X, Cuajungco MP, Atwood CS et al. Cu (II) potentiation of Alzheimer Aβ neurotoxicity. J Biol Chem 1999;274:37111-37116.
16. Estus S, Tucker HM, Rooyen CV et al. Aggregated amyloid-β protein induces cortical neuronal apoptosis and concomitant 'apoptotic' pattern of gene induction. J Neurosci 1997;17:7736-7745.
17. Mattson MP, Partin J, Begley JG. Amyloid β-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 1998;807:167-176.
18. Iverson LL, Mortishire-Smith RJ, Pollack SJ et al. The toxicity in vitro of β-amyloid protein. Biochem J 1995;311:1-16.
19. Huang X, Atwood CS, Hartshorn MA et al. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999;38:7609-7616.
20. Frausto da Silva JJR, Williams RJP. The Biological Chemistry of the Elements 2nd Ed. Oxford, UK: Clarendon Press, 1991.
21. Atwood CS, Scarpa RC, Huang X et al. Characterization of copper interactions with Alzheimer amyloid β peptides. J Neurochem 2000;75:1219-1233.
22. Atwood CS, Huang X, Moir RD et al. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. In: Sigel A, Sigel H, eds. Metal Ions in Biological Systems, Vol. 36. New York: Marcel Dekker, Inc., 1999, pp. 309-364.
23. Rubin E, Farber JL. Cell injury. In: Rubin E, Farber JL, eds. Pathology, 3rd Ed. Philadelphia: Lippincott-Raven Publishers, 1999, pp. 21-22.
24. Smith MA, Harris PLR, Sayre LM et al. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc Natl Acad Sci 1997;94:9866-9868.
25. Moir RD, Atwood CS, Romano DM et al. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations. Biochemistry 1999;38:4595-4603.
26. Cuajungco MP, Goldstein LE, Nunomura A et al. Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc. J Biol Chem 2000;275:19439-19442.
27. Opazo C, Huang X, Cherny RA et al. Metalloenzyme-like activity of Alzheimer's disease α-amyloid. J Biol Chem 2002;277:40302-40308.
28. Penkowa M, Giralt M, Moos T et al. Impaired inflammatory response to glial cell death in genetically metallothionein-I- and -II-deficient mice. Exp Neurol 1999;156:149-164.
29. Maret W, Vallee BL. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci 1998;95:3478-3482.
30. Frederickson CJ. Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol 1989;31:145-238.
31. Lee JY Cole TB, Palmiter RD et al. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci 2002;99:7705-7710.
32. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 2000;4:184-191.
33. Crapper McLachlan DR, Dalton AJ, Kruck TPA. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304-1308.
34. Cuajungco MP, Lees GJ. Diverse effects of metal chelating agents on the neuronal cytotoxicity of zinc in the hippocampus. Brain Res 1998;799:97-107.
35. Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676.
36. Padmanabhan G, Becue I, Smith JA et al. Clioquinol. In: Klauss E, Florey E, eds. Analytical Profiles of Drug Substances, Vol. 18. New York: Academic Press, 1989, pp. 57-90.
37. Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
38. Lue LF, Kuo YM, Roher AE et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-862.
39. Wang J, Dickson DW, Trojanowski JQ et al. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999;158:328-337.
40. Tabira T. Clioquinol's return: Cautions from Japan. Science 2001;292:2251-2252.
41. 12 and trace metals in brains of mice treated with clioquinol. J Neurol Sci 2000;173:40-44.
42. Regland B, Lehmann W, Abedini I et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 2001;12:408-414.
43. Master CL. In: 7th International Geneva/Springfield Alzheimer's Symposium. Geneva, Switzerland, April 2002.